Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Antibodies in Drug Discovery

Craig Malcolm's Biography



Craig Malcolm, Strategic Collaborations Manager, Promega UK Ltd

After receiving his PhD in Neurochemistry from St Andrews University, Dr Malcolm spent seven years in the pharmaceutical industry as a Team Leader in Molecular Pharmacology (Vernalis), developing cell-based assays and supporting drug discovery screening projects. After several more years in product development at PerkinElmer, and various other commercially-focussed roles in several other UK-based Life Science companies (Scientifica, Roche Applied Science), he joined Promega UK and is currently Strategic Collaborations Manager with a focus on new and emerging technology platforms for drug discovery and biologics.

Craig Malcolm Image

Novel Assay Formats using NanoLucĀ® Luciferase Technology for Homogeneous Immunoassay, Immunogenicity and Receptor-ligand Blockade

Monday, 6 March 2017 at 12:00

Add to Calendar ▼2017-03-06 12:00:002017-03-06 13:00:00Europe/LondonNovel Assay Formats using NanoLucĀ® Luciferase Technology for Homogeneous Immunoassay, Immunogenicity and Receptor-ligand BlockadeSELECTBIOenquiries@selectbiosciences.com

This talk will describe recently developed assays using NanoLucĀ® luciferase technology applied to PK/immunogenicity studies and a no-wash, homogeneous immunoassay format. In addition, data will be presented on cell-based BRET assays for quantifying antibody biologic mediated blocking of receptor-ligand interactions.


Add to Calendar ▼2017-03-06 00:00:002017-03-07 00:00:00Europe/LondonAntibodies in Drug DiscoverySELECTBIOenquiries@selectbiosciences.com